Breaking News Instant updates and real-time market news.

TROV

Trovagene

$2.32

-0.07 (-2.93%)

08:04
07/09/19
07/09
08:04
07/09/19
08:04

Trovagene begins enrollment of Phase 1b/2 study of onvansertib

Trovagene announced the initiation of patient enrollment of its Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin, or bevacizumab, for second-line treatment of patients with metastatic colorectal cancer, or mCRC, with a KRAS mutation, or NCT03829410. Trovagene is developing onvansertib, a first-in-class, third-generation, oral and highly-selective Polo-like Kinase 1 inhibitor that targets the key master regulator of tumor cell division, for the treatment of leukemias, lymphomas and solid tumor cancers. The trial is being conducted at USC Norris Comprehensive Cancer Center, Hoag Cancer Center and The Mayo Clinic, under the leadership of recognized colorectal cancer key opinion leaders.

  • 16

    Jul

TROV Trovagene
$2.32

-0.07 (-2.93%)

01/07/19
NBLE
01/07/19
INITIATION
Target $5.2
NBLE
Outperform
Trovagene initiated with an Outperform at Noble Financial
Noble Financial analyst Ahu Demir initiated Trovagene with an Outperform rating and $5.20 price target, stating that investors remain skeptical of PLK1 targeting but he foresees upside potential and likes TrovaGene's Onvansertib. He believes further data will be valuable to demonstrate anti-tumor activity and the safety profile of Onvansertib, Demir tells investors.
03/01/19
MAXM
03/01/19
NO CHANGE
Target $8
MAXM
Buy
Trovagene price target lowered to $8 from $18 at Maxim
Maxim analyst Jason McCarthy lowered his post-split price target for Trovagene to $8 from $18, which reflects dilution associated with future capital raises. The analyst keeps a Buy rating on the shares ahead of a "busy" American Association for Cancer Research annual meeting for the company in late March. Trovagene now has three funded clinical trials with Onvansertib, and as updates are provided in 2019, they should, if positive, support a higher valuation, McCarthy tells investors in a research note.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.